Protective Vaccine Researches in Shigella Infections
PDF
Cite
Share
Request
Invited Paper
P: 105-110
December 2011

Protective Vaccine Researches in Shigella Infections

J Ankara Univ Fac Med 2011;64(3):105-110
1. Ankara Üniversitesi Tıp Fakültesi Tıbbi Mikrobiyoloji Anabilim Dalı
No information available.
No information available
Received Date: 05.11.2010
Accepted Date: 04.04.2011
PDF
Cite
Share
Request

ABSTRACT

Shigella, a member of enterobacteriaceae, is endemic over the world and causes infections with high mortality rates especially in developing countries. Disease is more common among children under 5 years old and is an important cause of children death in world. World health organisation (WHO) consider the researches of a protective vaccine developement for shigellosis as a priority. Protective vaccines for Shigella infections are focused on conjugate vaccines based on bacterial O polysaccharide linked to a carrier protein administered by parenteral, oral or intranasal; live attenued vaccines conferring protection without causing disease; live oral vaccines obtained by genetic process following the discover of genes involved in pathogenesis; hybrid live vector Shigella vaccines; wide spectrum vaccines and invazin-complex vaccines. Last years, since virulance factors and pathogenesis of Shigella are discovered, promising vaccines for future are developed. In this review, vaccine developement strategies for obtaining protective and safe vaccines from past to now are investigated.

Keywords: Shigella, Vaccine researches

References

2024 ©️ Galenos Publishing House